Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
<p><strong>Objective</strong> To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn’s disease (CD) naïve to immunosuppressants and biologi...
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Sprache: | English |
| Veröffentlicht: |
BMJ Publishing Group
2019
|